ERS Genomics and Setsuro Tech Sign CRISPR/Cas9 License Agreement

Nobel prize winning CRISPR technology to be applied in development of genetically engineered cell and animal models

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Setsuro Tech, a biotechnology start-up using genome-editing techniques to develop and supply cell and animal models, today announced a non-exclusive license agreement granting Setsuro Tech access to ERS Genomics’ CRISPR/Cas9 patent portfolio for Japan.

Leave a Reply

Your email address will not be published. Required fields are marked *